Three new research signals reveal a widening chasm between prescription intent and patient action, and point toward what actually closes it.
Every day, physicians write prescriptions that patients never fill. Some never even pick them up. Others start, stop, and disappear from therapy within 90 days. The clinical encounter works. The commercial infrastructure behind it often does not.
This week’s research scan surfaced three findings that collectively explain why, and each one points to the same critical window: the 72 hours between a prescription being written and a patient standing at the pharmacy counter.
Pharma is finally measuring what matters
For years, patient support programs reported on activity: how many patients enrolled, how many calls were fielded, how many welcome kits shipped. These metrics felt accountable. They were, in practice, largely disconnected from what pharma commercial teams actually care about.
That is changing. At Access USA 2026, Nareda Mills, Global President of Patient Solutions at Inizio Engage, laid out the new measurement standard pharma leadership is now demanding from their patient services teams: time-to-therapy, prescription abandonment rates, and 90-day patient persistence.
The interval between prescription write and product receipt is no longer just a clinical concern. It is a commercial performance variable. Companies that can shorten it are translating patient support investment directly into brand revenue.
Source: Pharmaceutical Commerce / Access USA 2026, March 2026
The implication is significant for budget season. Patient education and activation programs that can demonstrate quantifiable impact on abandonment and persistence will hold their ground in H2 2026 planning conversations. Programs that report on process will face pressure.
This is a direct line from patient engagement investment to CCO-level reporting. The programs that survive the next budget cycle will be the ones that can show the numbers.
Most health apps fail, and the research finally explains why
A major scoping review published in JMIR mHealth and uHealth in May 2026 analyzed 52 peer-reviewed studies on user engagement across digital health applications, drawn from an initial pool of nearly 2,500 articles.
The central finding is uncomfortable reading for anyone who has invested in a pharma patient app: most mHealth interventions suffer from low adoption and rapid dropoff after initial use, with sustained engagement rarely extending beyond the first few interactions.
The researchers identified four frameworks for measuring digital health engagement. Only one predicted sustained impact: the goal-oriented model, where engagement is defined by whether the intervention actually helps the patient achieve a specific health objective, such as taking their medication, reaching a clinical milestone, or understanding their diagnosis.
Downloads, opens, and clicks are not engagement. The only metric that matters is whether the patient did the thing the program was designed to help them do.
Source: JMIR mHealth and uHealth, Aromatario et al., May 2026
This reframes the ROI question for pharma commercial teams entirely. An engagement platform that optimizes for open rates is solving the wrong problem. The measure of a patient engagement program should be whether it drives first-fill completion, PDC improvement, and 90-day persistence, not how many people tapped a notification.
Most platforms sold to pharma today are still optimized for the metric that looks good in a slide deck. The JMIR review provides peer-reviewed evidence that this approach does not work.
The structural leak at the moment of first fill
Even when patients intend to fill their prescription, and even when a copay assistance program exists to make it affordable, structural payer mechanisms can undermine that intent before the first pill is dispensed.
A March 2026 analysis from Drug Channels Institute, authored by Logan Melchione, VP of Patient Affordability at Paysign, put a number on the damage: by the time legacy copay solutions catch maximizer and accumulator activity, more than 35% of potential program savings have already been diverted.
New-to-brand abandonment is being driven not only by cost hesitation or patient confusion, but by structural payer mechanisms that undermine copay assistance before it can reach the patient. Modern claims-based solutions operating in real time at first fill, with identification accuracy of 97 to 98%, can prevent this erosion and protect both patient access and manufacturer investment.
Source: Drug Channels Institute / Paysign, March 2026
The precision affordability tools exist to address this. What they cannot fix on their own is the behavioral dimension of abandonment: the doubt, confusion, and lack of reinforcement that accumulate in the hours after a patient leaves the physician’s office.
Even when copay assistance works exactly as designed, patients still abandon. The absence of trusted, timely guidance in those first hours after prescription is itself a driver of non-adherence.
Three findings, one window
Taken together, these three signals describe the same problem from different angles. Pharma commercial teams are being held accountable to abandonment and persistence metrics they do not yet have the tools to move. Digital engagement platforms are failing because they were built to demonstrate activity, not achieve goals. And copay programs are losing a third of their value to structural erosion at the exact moment of first fill.
The period between a physician writing a prescription and a patient standing at the pharmacy counter is where the commercial outcome is determined. It is a window of roughly 72 hours, and for most patients, it passes in silence. No one calls to explain what the medication does. No one addresses the doubt that surfaces after leaving the office. No one reinforces the intent that existed in the exam room.
This is the window where Hoot operates. A short, MLR-approved physician video delivered by SMS reaches the patient at the moment when abandonment is most likely, with a trusted voice and a clear, goal-oriented message. No app to download. No account to create. No engagement metric that confuses activity with outcome.
The research agenda is converging on a clear picture of what works in patient engagement: goal-oriented design, trusted clinical voices, precision timing, and measurable impact on first-fill completion and 90-day persistence.
The gap between prescription intent and patient action is measurable. It is also closeable, with the right tools built for the right window.